This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Electronic cigarettes and asthma

Authoring team

Electronic Cigarettes and Asthma

  • evidence suggests that many electronic cigarettes (EC) compounds might contribute to the pathogenesis of asthma (1)
    • ECs and other electronic nicotine delivery systems (ENDSs) are now two to three times more popular among adolescents and young adults than among older adults, even though they were originally marketed as a form of smoking cessation assistance for adults with long-term cigarette use (2)

  • lung function seems to deteriorate by the use of EC in patients with asthma, while airway inflammation alters, with the aggravation of T-helper-type-2 (Th2) inflammation being the most prominent but not the exclusive effect (1)

  • EC seems to worsen asthma symptoms and the rate and severity of exacerbations in asthmatics who are current vapers (1)

  • studies have shown that ECs contain potentially toxic components such as propylene glycol (PG), vegetable glycerin (also known as glycerol) (VG), varying amounts of nicotine, and flavoring chemicals that may induce respiratory morbidity, especially on the inflamed, asthmatic airway (2)

  • data support a likely detrimental effect of vaping in asthmatic adolescents (3)

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.